Genotypes a patient to aid in individualizing a starting dose of thiopurines. Ordering prior to initiating therapy provides information for effective dosing, which may achieve maximum efficacy with minimized toxicity.
Prometheus TPMT Genetics helps classify patients as one of three genotypes (homozygous normal, heterozygous, or homozygous recessive). Because each patient metabolizes thiopurines differently, the efficacy and toxicity of thiopurines can vary widely from patient to patient. Knowledge of the TPMT genotype may reduce time to response, allow physicians to individualize dosing, identify patients in whom thiopurine therapy should be avoided and help reduce the risk of leukopenia.